Krajina: Malta
Jazyk: angličtina
Zdroj: Medicines Authority
ALBUMIN, HUMAN
Sanquin Plesmanlaan 125, 1066 CX Amsterdam, Netherlands
B05AA01
ALBUMIN, HUMAN 200 g/l
SOLUTION FOR INFUSION
ALBUMIN, HUMAN 200 g/l
POM
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
Withdrawn
2007-01-29
I B2.4. Design of the Patient Information Leaflet for Cealb ® INFORMATION FOR THE PATIENT: Read this package leaflet carefully when you have some time to yourself. If you have further questions, please ask your physician or your pharmacist. GENERAL CHARACTERISTICS The product is marketed under the name of Cealb®. The commercial packing of Cealb® consists of: * A vial with 10 ml, 20 ml, 50 ml or 100 ml of Cealb®. The product is delivered as a solution for infusion for intravenous use. The active substance is albumin. The product contains 200 grams of protein per litre, of which at least 95% is albumin. Along with albumin, the product contains other proteins, such as pre-albumin and haptoglobin. The product also contains the following other ingredients: sodium chloride, sodium caprylate, mandelic acid and water for injections. Cealb® is a protein purified from donor blood. This donor blood is obtained from healthy, voluntary, non- remunerated donors. These individuals satisfy the requirements imposed on blood donors in the Netherlands. All blood donors are tested for several pathogens such as: • the AIDS virus; • the hepatitis B and C viruses (which cause jaundice); • Treponema pallidum (the causative agent of syphillis). These pathogens could not be detected in the donors. Furthermore, this product has undergone a ”virus reducing treatment”. This “virus reducing treatment” kills or eliminates as many as possible of the viruses still present, thus making the risk of virus transfer exceptionally small. Albumin is an important protein in the blood. Albumin provides for the transport of endogenous substances as well as certain medicinal products. In addition, albumin is important in the regulation of the blood volume through maintenance of the so-called c Prečítajte si celý dokument
Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE PRODUCT The trade name of the product is Cealb®. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2.1 ACTIVE INGREDIENT Cealb® consists of a protein fraction prepared from human venous plasma. The preparation is delivered as a sterile and pyrogen-free solution and has a protein concentration of 200 g/l, of which at least 95% is albumin. 2.2 VIRAL SAFETY Cealb® is prepared from venous plasma by means of ethanol fractionation. The plasma has to be derived from voluntary, nonremunerated donors who satisfy the requirements of the Blood Transfusion Council of the Netherlands Red Cross. This means, among other things, that every individual donation has been tested and found negative for hepatitis B surface antigen (HBsAg), for antibodies against human immunodeficiency viruses 1 and 2 (HIV-1 and HIV-2, the inducers of AIDS) and for antibodies against hepatitis C virus. Manufacturing by means of ethanol fractionation and the pasteurisation of Cealb® (heating of the infusion solution at 60 °C during 10 hours) ensure that the risk of transmission of viral diseases, in particular AIDS, hepatitis B and hepatitis non-A, non-B (including hepatitis C) will be extremely small. 3. PHARMACEUTICAL FORM Cealb® is delivered as a solution for infusion for intravenous use. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Cealb® is indicated especially for application in clinical situations where large amounts of plasma protein with low sodium levels must be administered. After dilution to an iso-oncotic solution Cealb® can be applied in cases of volume deficit. Cealb® is indicated in the following situations: - imminent or existing cases of shock such as during severe bleeding and burns - extracorporeal circulation - sepsis or s Prečítajte si celý dokument